IPR In Trips Compliance.
IPR in TRIPS Compliance:
The TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights) is part of the WTO framework, setting minimum standards for IP protection that member countries must implement. It covers:
Patents – standards for invention protection (including pharmaceuticals, biotechnology, and software).
Copyrights – protection for literary, artistic, and software works.
Trademarks & Geographical Indications – protection for brands and origin-linked products.
Enforcement – measures against infringement, border enforcement, and remedies.
Flexibilities – compulsory licensing, parallel importation, exceptions for public health.
Compliance with TRIPS often leads to domestic legal reforms, patent disputes, and balancing innovation incentives with public access.
Key Areas of TRIPS Compliance in IPR
Patentability – Novelty, inventive step, and industrial applicability.
Exceptions & Compulsory Licensing – Allowing governments to issue licenses for public health emergencies.
Enforcement – Civil, criminal, and border measures against IP infringement.
Dispute Resolution – WTO panels for member countries failing to comply.
Detailed Case Laws in TRIPS Compliance
1. Canada – Patent Protection for Pharmaceuticals (Canada – Patent Protection for Pharmaceuticals, 2000)
Issue: Canada’s laws allowed early working of patents and export of generics, allegedly violating TRIPS.
Facts: The EU and US challenged Canada’s system for pharmaceutical patents.
Decision: WTO panel recognized some TRIPS flexibilities, but Canada had to amend legislation to fully comply.
Significance: Shows TRIPS allows some flexibility for public health and generic exports, but countries must align domestic law with international IP standards.
2. India – Novartis AG v. Union of India (2013, Supreme Court of India)
Issue: Patentability under TRIPS and India’s Section 3(d) (prevention of evergreening patents in pharma).
Facts: Novartis sought patent for Glivec (cancer drug); India rejected it citing lack of significant innovation.
Decision: Supreme Court upheld rejection; only truly innovative pharmaceutical products are patentable.
Significance: Balances TRIPS compliance with public health priorities, showing how TRIPS allows national discretion in patent standards.
3. Brazil – Compulsory Licensing for HIV/AIDS Drugs (2007)
Issue: TRIPS compliance vs. public health needs.
Facts: Brazil issued compulsory licenses to manufacture generic antiretroviral drugs, facing potential trade disputes.
Decision: WTO and TRIPS allowed this under public health exceptions (Article 31).
Significance: Demonstrates TRIPS flexibilities in access to medicines, especially for health emergencies.
4. United States – U.S. – Section 110(5) of the Copyright Act (WTO Panel, 2000)
Issue: Alleged TRIPS violation in U.S. copyright exceptions for educational broadcasts.
Facts: The EU argued U.S. exceptions conflicted with TRIPS copyright standards.
Decision: WTO panel examined compliance and recommended amendments to align with TRIPS enforcement and protection standards.
Significance: Highlights the need for domestic law harmonization with TRIPS, even for copyright exceptions.
5. Australia – Pharmaceutical Patents & Compulsory Licensing (2002–2005)
Issue: TRIPS compliance in balancing patent protection and public access.
Facts: Generic manufacturers challenged pharmaceutical patents; government issued guidelines for compulsory licensing.
Decision: Courts upheld TRIPS-compliant national policies allowing limited government-authorized generics.
Significance: Shows how TRIPS does not prevent national policies supporting affordable healthcare.
6. WTO Dispute: India – Patentability Standards
Issue: Whether India’s patent standards for incremental pharmaceutical innovations (Section 3(d)) comply with TRIPS.
Facts: U.S. and EU raised concerns about TRIPS consistency.
Decision: WTO acknowledged that countries can set stricter patentability criteria as long as TRIPS minimum standards are met.
Significance: Reinforces sovereign flexibility in patent law under TRIPS, especially for health policy.
7. Thailand – Compulsory Licensing for Antiretroviral Drugs (2007)
Issue: Similar to Brazil, TRIPS vs. public health.
Facts: Thailand issued licenses for generic HIV drugs, facing threats of trade sanctions.
Decision: TRIPS recognized these as legal under Article 31, affirming public health exception.
Significance: Strengthens the argument that TRIPS allows flexibility for developing nations.
Key Takeaways
TRIPS sets minimum standards, but countries have flexibility to implement stricter or more socially-oriented policies.
Public health exceptions (Articles 31 & 30) allow compulsory licensing for essential medicines.
Patentability standards can be tailored to prevent evergreening or minor modifications from extending monopoly.
Enforcement measures must be compliant but balanced; domestic law may include civil, criminal, and border protections.
Dispute settlement is available through WTO panels for compliance issues.
Global examples (India, Brazil, Thailand, U.S., Canada) show how TRIPS compliance is balanced with national interests.
RELATED Blog
comments